The deal also now includes exclusive rights for China's largest vaccine company to explore a collaboration on GSK's (GSK.L), opens new tab respiratory syncytial virus (RSV) vaccine, Arexvy ...
The deal also now includes exclusive rights for China's largest vaccine company to explore a collaboration on GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, in China, the world's No.2 ...
Under the revised agreement, GSK will collaborate exclusively with Zhifei on the commercialization of its respiratory syncytial virus vaccine Arexvy in China for an initial period of 10 years ...
In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) for use in adults ages 50 to 59 at risk of RSV-related lower respiratory tract disease due to underlying conditions ...
GSK’s third-quarter Vaccine sales declined 15% due to lower sales of its RSV vaccine Arexvy and shingles vaccine, Shingrix. Arexvy generated £188 million during the quarter, down 72% year over ...
GSK said Zhifei also has agreed to exclusively engage in discussions of a potential collaboration on the commercialisation of its respiratory syncytial virus vaccine, Arexvy, subject to regulatory ...
has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to include adults aged 50-59 at increased risk. Since September 2023, GSK’s RSV vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback